In recent years, a number of preclinical models have shown that cannabinoids may be highly effective at improving inflammation and, therefore, may be a potential treatment for inflammatory bowel diseases.
Although they are less likely to receive it, patients hospitalized with inflammatory bowel disease should be placed on venous thromboembolism prophylaxis to reduce the number of preventable VTE events.
Treatment with ontamalimab was associated with both clinical and symptomatic remission in patients with ulcerative colitis (UC), according to data presented at the 2019 AIBD Annual Meeting held in Orlando, Florida.
Inflammatory bowel disease (IBD) diagnosis appears to be associated with high levels of anxiety and depression in children, however, new study findings presented at the 2019 AIBD Annual Meeting suggest that many of these patients may not be receiving appropriate mental health services.
Treatment with adalimumab or infliximab in biologic-naive patients with Crohn disease or ulcerative colitis demonstrated similar outcomes on Patient-Reported Outcomes Measurement Information System measures and rates of corticosteroid-free remission.
“The data indicate that more conservative periodontal therapy might initially be considered for IBD patients with advanced periodontal disease for whom PPI are prescribed as a component of their IBD treatment,” the authors concluded.
Combination biologic therapy may be an effective treatment option for patients with inflammatory bowel disease (IBD) who are refractory or have a concomitant autoimmune disease that is inadequately controlled by biologic monotherapy.
Proactive monitoring of adalimumab trough concentrations in children was associated with higher corticosteroid-free sustained remission and biologic remission rates compared with reactive monitoring in pediatric patients with Crohn disease.
IBD clinical trials have become increasingly complex as more specific clinical endpoints have gathered support within the academic arena. There has also been an emphasis on long-term extension safety and efficacy data which can further complicate recruitment.